Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 29, 2004

View Archived Issues

Japanese approval for Hepsera

New indication for Sandostatin injection approved in Japan

FDA approval for Fosrenol

Guilford researchers present novel NAALADase inhibitors

Novel antibacterial methionyl tRNA synthetase inhibitors claimed by Replidyne

New antirotavirus agents prepared and tested at ViroPharma

Encysive scientists design new urotensin II antagonists

New GSK-3beta inhibitors and their use in Alzheimer's disease and other disorders

New alpha2delta-selective calcium channel ligands discovered at Pfizer

Gruenenthal describes new NOS inhibitors with analgesic activity

New fungal derivative with antitumor and antiproliferative properties

Enrollment progressing ahead of schedule in Ranexa angina study

CuraGen highlights pipeline progression

CuraGen and Bayer advance diabetes compound into preclinical development

Merck KGaA grants Lilly rights to 5-HT2A antagonist for insomnia

Serono and Paratek to develop oral disease-modifying treatment for MS

Approvable letter for Alvesco for persistent asthma

Allergan files IND for neuropathic pain compound

Cloretazine receives orphan drug status

Phase II study of IMOxine in renal cell carcinoma opens enrollment

GlaxoSmithKline acquires rights to Albugon

Lobeline enters clinical trials for methamphetamine addiction

Clearazide set to enter phase II/III studies in 2005

Novo Nordisk terminates development of balaglitazone

CY-401 active against VRSA in preclinical study

International Wex Technologies changes corporate name

Preclinical and clinical data support the efficacy of DA-8159 in erectile dysfunction

Torcetrapib increases plasma HDL cholesterol levels and prevents atherosclerosis in rabbits

Short-term efficacy of a combination of JTT-705 plus pravastatin in type II dyslipidemia

Rimonabant reported to improve insulin response in obese patients with dyslipidemia

Clinical phase I/II data on CAT-192 in diffuse systemic sclerosis

AMG-714 safe, active in rheumatoid arthritis

TNF-alpha antibody evaluated in rheumatoid arthritis patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
HX-16108 holds promise for treating inflammatory skin diseases
BioWorld Science
Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has...